Splenic T and B lymphocytes and their mitogenic response in untreated Hodgkin's disease
- PMID: 6965606
- DOI: 10.1002/1097-0142(19800215)45:4<767::aid-cncr2820450426>3.0.co;2-4
Splenic T and B lymphocytes and their mitogenic response in untreated Hodgkin's disease
Abstract
The splenic T and B cell distribution in 79 patients with untreated Hodgkin's disease was quite similar to that in 15 control patients with non-Hodgkin's lymphoma or carcinoma. The mean T lymphocyte percentage was slightly higher in involved spleens than in uninvolved spleens of patients with Hodgkin's disease. There was no significant difference in the T and B cell distribution between tumor area and tumor-free area of the same spleens of Hodgkin's disease patients. Splenic T and B cell distribution did not correlate well with the clinical features of Hodgkin's disease. The splenic T cell percentage was significantly lower than that of the peripheral blood T cell percentage (P less than 0.05), while the splenic B cell percentage was significantly higher than peripheral blood B cell percentage (P less than 0.01) in 13 patients with untreated Hodgkin's disease. The splenic T lymphocyte response to PHA was significantly higher than the peripheral blood T lymphocyte response (P less than 0.05), and the splenic B lymphocyte response to PHA, in the presence of irradiated autologous splenic T lymphocytes, was also significantly higher than the peripheral blood B lymphocyte response (P less than 0.05) in 8 and 6 patients with untreated Hodgkin's disease, respectively. Since the control splenic cells, utilized in this study were obtained not from patients with non-neoplastic disease, but from patients with neoplastic disease other than Hodgkin's disease, our data are not conclusive, but only suggestive of normal T and B cell distribution and function in uninvolved spleens of patients with untreated Hodgkin's disease.
Similar articles
-
Role of suppressor cells in depression of T lymphocyte proliferative response in untreated and treated Hodgkin's disease.Cancer. 1980 Apr 15;45(8):2102-8. doi: 10.1002/1097-0142(19800415)45:8<2102::aid-cncr2820450818>3.0.co;2-i. Cancer. 1980. PMID: 6445226
-
Tissue T-lymphocytes in untreated Hodgkin's disease: morphologic and functional correlations in spleens and lymph nodes.Cancer. 1982 Jul 15;50(2):259-68. doi: 10.1002/1097-0142(19820715)50:2<259::aid-cncr2820500216>3.0.co;2-b. Cancer. 1982. PMID: 6979382
-
B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.J Clin Invest. 1973 Dec;52(12):3064-73. doi: 10.1172/JCI107505. J Clin Invest. 1973. PMID: 4201499 Free PMC article.
-
A marker and putative pathoantigen of Hodgkin's cells.Recent Results Cancer Res. 1989;117:91-8. doi: 10.1007/978-3-642-83781-4_10. Recent Results Cancer Res. 1989. PMID: 2690234 Review.
-
Hodgkin's disease and anergy.Blut. 1979 Jan 22;38(1):1-7. doi: 10.1007/BF01082922. Blut. 1979. PMID: 365274 Review.
Cited by
-
Impaired B-lymphocyte reactivity in patients with Hodgkin's disease and non-Hodgkin-lymphomas.Blut. 1981 May;42(5):271-81. doi: 10.1007/BF00996844. Blut. 1981. PMID: 7016220
-
The role of the spleen in leukemias and lymphomas including Hodgkin's disease.Experientia. 1985 Feb 15;41(2):215-24. doi: 10.1007/BF02002616. Experientia. 1985. PMID: 3882450 Review. No abstract available.
-
Effect of arginase on splenic killer cell activity in patients with gastric cancer.Dig Dis Sci. 1994 May;39(5):1107-12. doi: 10.1007/BF02087565. Dig Dis Sci. 1994. PMID: 8174424
-
Cell-mediated cytotoxic activity of spleen cells from patients with gastric carcinoma.Jpn J Surg. 1988 Mar;18(2):164-71. doi: 10.1007/BF02471426. Jpn J Surg. 1988. PMID: 2969062
-
Evaluation of the circulating and splenic lymphocyte subpopulations in patients with non-Hodgkin lymphomas and Hodgkin's disease using monoclonal antibodies.Blut. 1983 Jul;47(1):41-51. doi: 10.1007/BF00321049. Blut. 1983. PMID: 6222774
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical